APA (7th ed.) Citation

BA, d. C., S, C., MA, P., JP, M., CR, R., EP, L., . . . SA, N. (2026). HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort. Breast (Edinburgh, Scotland), 89, 104849. https://doi.org/10.1016/j.breast.2026.104849

Chicago Style (17th ed.) Citation

BA, de Castro, et al. "HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from a Real-world Cohort." Breast (Edinburgh, Scotland) 89 (2026): 104849. https://doi.org/10.1016/j.breast.2026.104849.

MLA (9th ed.) Citation

BA, de Castro, et al. "HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from a Real-world Cohort." Breast (Edinburgh, Scotland), vol. 89, 2026, p. 104849, https://doi.org/10.1016/j.breast.2026.104849.